CN116096861A - 过继性细胞转移的增强 - Google Patents

过继性细胞转移的增强 Download PDF

Info

Publication number
CN116096861A
CN116096861A CN202180032504.XA CN202180032504A CN116096861A CN 116096861 A CN116096861 A CN 116096861A CN 202180032504 A CN202180032504 A CN 202180032504A CN 116096861 A CN116096861 A CN 116096861A
Authority
CN
China
Prior art keywords
cells
cell
immune
mitochondria
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180032504.XA
Other languages
English (en)
Chinese (zh)
Inventor
A·舒勒
S·基普里亚诺夫
N·杜马蒂奥兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Selivi Co
Original Assignee
Selivi Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selivi Co filed Critical Selivi Co
Publication of CN116096861A publication Critical patent/CN116096861A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180032504.XA 2020-04-03 2021-04-02 过继性细胞转移的增强 Pending CN116096861A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063005167P 2020-04-03 2020-04-03
US63/005,167 2020-04-03
PCT/US2021/025643 WO2021203046A1 (en) 2020-04-03 2021-04-02 Enhancement of adoptive cell transfer

Publications (1)

Publication Number Publication Date
CN116096861A true CN116096861A (zh) 2023-05-09

Family

ID=75919371

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180032504.XA Pending CN116096861A (zh) 2020-04-03 2021-04-02 过继性细胞转移的增强

Country Status (7)

Country Link
US (2) US20210309967A1 (https=)
EP (1) EP4127141A1 (https=)
JP (1) JP2023521037A (https=)
CN (1) CN116096861A (https=)
AU (1) AU2021246112A1 (https=)
CA (1) CA3173391A1 (https=)
WO (1) WO2021203046A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12419913B2 (en) 2019-02-08 2025-09-23 Dna Twopointo, Inc. Modification of CAR-T cells
CN118541160A (zh) * 2021-10-06 2024-08-23 赛立维公司 通过促进优越的适应性免疫细胞群体增强过继细胞转移
CA3257638A1 (en) 2022-06-10 2023-12-14 Cellvie Ag COMPOSITION AND CRYOCONSERVATION PROCESS OF MITOCHONDRIA
US20260041767A1 (en) * 2022-08-02 2026-02-12 National University Corporation Hokkaido University Methods of improving cellular therapy with organelle complexes
WO2024076572A1 (en) * 2022-10-06 2024-04-11 Mitrix Bio Inc. Formulations and methods for cellular therapies involving chimeric antigen receptors
WO2024097901A1 (en) * 2022-11-02 2024-05-10 Fate Therapeutics, Inc. Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting cd79b

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016008937A1 (en) * 2014-07-16 2016-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the intercellular transfer of isolated mitochondria in recipient cells
CN109152795A (zh) * 2016-01-15 2019-01-04 儿童医学中心公司 线粒体和组合的线粒体试剂的治疗用途
CN109983120A (zh) * 2016-11-14 2019-07-05 白雁生物技术公司 含有外源线粒体的天然杀伤细胞和含有其的药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2694549B1 (en) 2011-04-08 2018-08-15 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
US11491480B2 (en) 2014-06-13 2022-11-08 Children's Medical Center Corporation Products and methods to isolate mitochondria
AU2015343013B2 (en) * 2014-11-05 2020-07-16 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
JP7524157B2 (ja) * 2018-07-22 2024-07-29 ミノヴィア セラピューティクス リミテッド 脳疾患のミトコンドリア増強療法
KR20210042125A (ko) * 2018-08-07 2021-04-16 퍼듀 리서치 파운데이션 Car t 세포의 회생
EP3837359A4 (en) * 2018-08-14 2022-05-11 Imel Biotherapeutics, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MITOCHONDRIAL DISEASES OR DISORDERS AND HETEROPLASMIA
CA3172402A1 (en) * 2020-03-31 2021-10-07 Minovia Therapeutics Ltd. Mitochondria-enriched genetically engineered cells and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016008937A1 (en) * 2014-07-16 2016-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the intercellular transfer of isolated mitochondria in recipient cells
CN109152795A (zh) * 2016-01-15 2019-01-04 儿童医学中心公司 线粒体和组合的线粒体试剂的治疗用途
CN109983120A (zh) * 2016-11-14 2019-07-05 白雁生物技术公司 含有外源线粒体的天然杀伤细胞和含有其的药物组合物
US20190269731A1 (en) * 2016-11-14 2019-09-05 Paean Biotechnology Inc. Natural killer cell containing exogenous mitochondrium and pharmaceutical composition comprising same

Also Published As

Publication number Publication date
JP2023521037A (ja) 2023-05-23
EP4127141A1 (en) 2023-02-08
AU2021246112A1 (en) 2022-11-10
WO2021203046A1 (en) 2021-10-07
US20240052310A1 (en) 2024-02-15
CA3173391A1 (en) 2021-10-07
US20210309967A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
EP4592310A2 (en) Novel antigen binding domains and synthetic antigen receptors incorporating the same
CN106068276B (zh) 具有针对T细胞受体beta恒定区的抗原结合域的嵌合抗原受体(CAR)
CN114761037A (zh) 结合bcma和cd19的嵌合抗原受体及其用途
US20240052310A1 (en) Enhancement of adoptive cell transfer
KR20200069358A (ko) 키메라 항원 수용체 발현 세포의 제조 방법
JP2021529559A (ja) グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用
JP2021530503A (ja) 標的特異的融合タンパク質を使用してｔｃｒをリプログラミングするための組成物及び方法
JP2018519842A (ja) 免疫細胞の有効性および増大を改善する方法
JP2019514393A (ja) 細胞に基づくネオ抗原ワクチンおよびその使用
EP3558348A1 (en) Engineered t cells for the treatment of cancer
CN107995913A (zh) 使用融合蛋白对tcr重编程的组合物和方法
KR20230129979A (ko) 수지상 세포 활성화 키메라 항원 수용체 및 이의 용도
TW201446794A (zh) 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向
JP7524465B2 (ja) 免疫細胞機能の改善
CN116249769A (zh) 功能增强的免疫细胞
CN118108857A (zh) 免疫细胞靶向性构建体
WO2022152862A1 (en) Her2 single domain antibodies variants and cars thereof
US20240398950A1 (en) Enhancing adoptive cell transfer by promoting a superior population of adaptive immune cells
WO2022104056A2 (en) Modulating bhlhe40 in the differentiation of type 1 regulatory t cells and controlling t cell exhaustion
WO2022079270A1 (en) Anti-gpc4 single domain antibodies
JP2023541694A (ja) がん治療剤としての二重特異的抗原結合分子を有するｃａｒ発現ナチュラルキラー細胞の生成方法及び組成物
HK40093031A (zh) 过继性细胞转移的增强
HK40115153A (zh) 通过促进优越的适应性免疫细胞群体增强过继细胞转移

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40093031

Country of ref document: HK